Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group): Lipid evaluation in a Mexican cohort

Manuel Odín De los Ríos-Ibarra, José Luis Leiva-Pons, Humberto Rodríguez-Reyes, Marco Antonio Alcocer-Gamba, Jorge Cortés-Lawrenz, Frida María Vizcaíno-Rios, Jaime Barragán-Luna, Julio Iván Farjat-Ruiz, Luis R. Virgen-Carrillo, Francisco Padilla-Padilla, Abel Pavia-López, Enrique C. Morales-Villegas, Natalie C. Ward, Leslie Marisol Lugo-Gavidia

Research output: Contribution to journalArticlepeer-review

Abstract

Background and aims: Dyslipidaemia is a significant risk factor for cardiovascular disease in the Mexican population. This analysis aimed to describe the baseline LDL-c levels of patients presenting to cardiovascular clinics and evaluate the proportion who achieved their risk-based LDL-c goals as recommended by 2021 ESC prevention guidelines. Methods: The REMECAR registry is an observational study of patients attending a specialized cardiovascular clinic for their first visit. The cardiovascular risk was retrospectively determined using the 2021 ESC guideline stratification and the SCORE2 and SCORE-OP. Results: A total of 5443 patients were included in the analysis. Within this population, 55.96% presented as very high, 39.98% as high and 4.06% as moderate to low risk. 63% of the participants were not on any lipid-lowering treatment at entry, while 12.4% were receiving high-intensity statin therapy. Patients presenting with established atherosclerotic cardiovascular disease had a mean LDL-c of 90.9 ± 40.7 mg/dL. Of these, 14.1% were achieving LDL-c levels of 70–55 mg/dL and 19.3% were achieving LDL-c levels <55 mg/dL. In diabetic patients at very high risk, only 25.7% achieved their LDL-c goal. Finally, in patients without another risk factor and very high-risk evaluated by SCORE2 & SCORE-OP, only 14% of patients achieved their LDL-c goals. Conclusions: An important number of patients were not receiving any lipid-lowering therapy. Furthermore, in those who were, a significant portion did not achieve LDL-c recommended thresholds. Our results underline the urgent need to improve the prescription and optimization of lipid-lowering therapy as the current management appears to be insufficient for achieving optimal recommended goals. Identifying key barriers in lipid management is fundamental to establishing better strategies and health system policies to reduce cardiovascular risk.

Original languageEnglish
Pages (from-to)32-39
Number of pages8
JournalAtherosclerosis Plus
Volume50
DOIs
Publication statusPublished - Dec 2022

Fingerprint

Dive into the research topics of 'Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group): Lipid evaluation in a Mexican cohort'. Together they form a unique fingerprint.

Cite this